Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2020 | Teclistamab: BCMA x CD3 bispecific antibody in RRMM

Saad Usmani • 27 May 2020
ASCO 2020
Multiple Myeloma Teclistamab

Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, talks through the results from the Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Saad Usmani

The value of iwHRMM and wrap-up of the 2025 meeting
2:23
The value of iwHRMM and wrap-up of the 2025 meeting
Saad Usmani • 24 Oct 2025
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Myeloma updates from EHA 2022: the DETERMINATION trial, the role of transplant, and exciting novel immunotherapies
Saad Usmani • 15 Jul 2022
iwGPRC5D 2025: highlights from the workshop
2:44
iwGPRC5D 2025: highlights from the workshop
Saad Usmani • 22 Mar 2025
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
Saad Usmani • 4 Nov 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Saad Usmani • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Saad Usmani • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Saad Usmani • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Saad Usmani • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals